<DOC>
	<DOC>NCT01018173</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled parallel arm study will assess efficacy and safety and the effects of taspoglutide on cardiovascular events in patients with inadequately controlled type 2 diabetes mellitus and established cardiovascular disease. Patients will be randomized to receive either taspoglutide subcutaneously (sc) 10mg weekly for 4 weeks followed by 20mg sc weekly, or weekly sc placebo, in addition to background anti-hyperglycemic medication and standard of care treatment for cardiovascular disease. Anticipated time on study treatment is up to 2 years. Target sample size is 2000 patients.</brief_summary>
	<brief_title>A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>adult patients, &gt;18 years of age diabetes mellitus type 2 HbA1c &gt;/=6.5% and &lt;/=10% at screening BMI &gt;/=23kg/m2 cardiovascular disease with onset &gt;/=1 month prior to screening diagnosis or history of type 1 diabetes or secondary forms of diabetes acute metabolic diabetic complications within past 6 months severe hypoglycemia &lt;/=1 month prior to screening clinically significant gastrointestinal disease history of chronic or acute pancreatitis current New York Heart Association (NYHA) class IV heart failure or posttransplantation cardiomyopathy severely impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>